<DOC>
	<DOC>NCT01751152</DOC>
	<brief_summary>This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn's disease.</brief_summary>
	<brief_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Moderately to severely active Crohn's disease, defined as a Crohn's disease activity index (CDAI) of 220450 (both inclusive) at Visit 2 (Day 0, Dosing), with evidence of inflammation confirmed by a Creactive protein (CRP) above or equal to 10 mg/L or endoscopic verification (according to endoscopy imaging manual) performed at Visit 1 (Day 28 to 7, Screening) Biologicna√Øve subjects or biologicexperienced for the treatment of Crohn's disease. Biologicexperienced subjects are eligible if they have not failed more than one marketed biologic therapy for the treatment of Crohn's disease due to lack of efficacy (primary or secondary efficacy failures) Body mass index (BMI) equal to or above 38.0 kg/m^2 Any of the following: symptomatic bowel obstruction, short bowel syndrome, ileostomy or colostomy, surgical bowel resection within 6 months prior to randomisation, total colectomy or subtotal colectomy with less than 20 cm colon remaining, any abscesses not adequately treated History of dysplasia in the colon Any active or ongoing bacterial infections within 4 weeks prior to randomisation, unless treated and resolved with appropriate therapy Any history of serious recurrent infections requiring hospitalisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>